T h e animals used \\,ere male rats from the Heiligenberg-strain, 'I to 15 weeks old. Carrier-free 14JCe(III) or 911'(111) was injected intravenously as chloride (3 to 5 pc per animal). T h e following chelates were used : (i) Xa3Ca-DTPX, (ii) Ka3Co-DTPX (excess of free D T P A 6 0.5 per cent), and (iii) ?;a,Zn-DTP-4 (excess of free DTP--1,< 0.2 per cent). Different dosages of these chelates were administered either intravenously and simultaneously with l"Ce or intraperitoneally on the 2nd, 5th and 8th day following the injection of l4%e and "Y, respectively. In the former experiment, the animals were sacrificed 48 hours after the administration of 14Te, in the latter series-on the 12th day.
The activity of the ashed organs was assayed by means of an end-window counter. The radionuclide content of the skeleton was assumed to be 20 times that of a femur. In the experiments where Co(I1)-and Zn(I1)-DTPA labelled by G°Co and G5Zn, respectively, were used, the retention of the radionuclide was determined by in vivo whole-body counting; a plastic scintillator (NE 102; 7 in. diameter, 5 in. deep) was used.
RESULTS
The maximal effect of the metal chelates is obtained with simultaneous administration. The results of this series are shown in figures 1 to 3, the 144Ce-content of the organs being expressed as percentage of the average of 20 untreated animals. I n the control group, liver, skeleton and kidneys retained of DTPA-chelates. DTPA was administered simuItaneously with 144Ce. Each point is the average of 6 to 10 rats ; the vertical bars indicate fiducial limits (P = 0.05).
35.8, 33-7 and 2-32 per cent, respectively, of the administered 14Te-amount. I n no case was a linear dependence of effectiveness upon dosage obtained. On the other hand, the shape of the dose-effect-curves is obviously identical for all three chelates. There is no significant difference in the efficacy of Ca-and Zn(I1)-DTPA while the effectiveness of Co(I1)-DTPA is apparently reduced as compared with Ca-DTPA. I n the experimental series where the chelates were given with a delay and the activity of the organs was assayed on the 12th day, the liver in the control group (23 rats) retained 15.0 per cent of the 'We-dose, the kidneys--0.61 per cent. Although it is known that there is no elimination of 144Ce from the bones, the skeletal content in the control group (18.5 per cent) was lower than in the preceding experiment. This is due to the different age of the animals in both experiments, a factor which exerts a significant influence on the skeletal retention (Schmautz 1964 ). In the glY-control group (27 animals), liver, skeleton and kidneys retained 0.95, 64.8 and 1-32 per cent respectively.
I n all cases, parallel dose-effect curves were obtained so that (after omission of the lowest dosages in the 14Te-series which deviate distinctly from a linear regression) the relative potency of Ca-DTPA could be calculated (cf. Finney 1952). The relative potency p indicates the factor by which the effectiveness of Ca-DTPA is higher than that of Co(1I)-and Zn (I1) Each point is the average of 10 rats.
100--80
The retention of 60Co and 65Zn after a single or repeated administration of labelled Co(I1)-and Zn(I1)-DTPA, respectively, is sho\vn in figures 6 and 7. Using the data obtained in the single exposure study, the expected retention of Each point is the average of 10 rats.
Potency (p) Heller and Catsch (1959) , the effectiveness of any metal-chelate J l L in removing a carrier-free radiometal "M from the body, in a first approximation, should be proportionately related to:
K are the stability constants of the corresponding 1 : l-chelates, the brackets indicate concentrations, and the influence of PH is taken into account by the distribution coefficient a (Heller and Catsch 1959) . I t can be reasonably assumed that (Ca), (CO) and (Zn) in the mammalian organism are virtually invariable. The log-values of the stability constant of Co (11) This implies necessarily that (CO) and (Zn) are negligibly small, even if (Co)tOta1 and (Zn)tot,l are raised by the administration of the corresponding DTPA-chelate.
Depending on the organ taken as basis for the calculations, on the kind of radionuclide, and, finally, on the time of DTPA-treatment, the determination of the relative potency of Ca-DTP,4 yields inconsistent figures (see table and figures 1 to 3). The esistent discrepancies cannot be easily explained, if they turn out to be real, and additional assumptions would be needed. From the practical view-point and taking into account the rather broad fiducial range of the relative potencies listed in the table, the apparent differences should by no means be overestimated, and it can be stated that there are, if at all, only minor differences in the efFicacy of the three chelates.
For technical reasons, i.e. the limits set up by the solubility of the chelates, our earlier studies (Catsch 1964 b) did not succeed in exact evaluation of the toxic dosages of Co(11)-and Zn(I1)-DTPA. It could be stated only that in chronic toxicity tests Zn(I1)-DTPA is at least ten times, and Co(I1)-DTPA about four times less toxic than Ca-DTPA. If a p-value of 2 for Ca-DTPAIZn(I1)-DTPh (after averaging the figures of the table) is assumed, it follows that the therapeutic index of Zn(I1)-DTPA is at least five times higher than that of Ca-DTP-4. TTTith Co(I1)-DTPA, the increase of the therapeutic index is less pronounced.
So far, no data are available for the mobilization by Zn(1I)-and Co(11)-DTPA of other practically important metal ions, such as Pb, Fe or 23Tu. It is fairly unlikely, however, that relative potencies would be obtained fundamentally different from lUCe and "Y.
The non-linear relationship between dosage and effect which was demonstrated with simultaneous administration of the chelators (see figures 1 to 3) suggests a 'compartmentalization ' of the given organ, i.e. the organ has to be conceived as composed of several compartments, each of which is characterized by different affinities toward the radiometal and, therefore, by differing response to the chelator (Catsch 1961 (Catsch , 1964a . Delayed administration of the chelator (see figures 4 and 5) is followed by a pronounced loss in effectiveness as well as by a marked change of the shape of the dose-effect curves. Obviously, the bulk of the radiometal becomes transferred from the loosely bound state into the compartment(s) with a more stable binding. It is not at all unexpected that different radiometals, such as radiocerium and radioyttrium, behave in this In the case of multiple doses, the percentage refers to the total dose. Each point is the average of 3 rats. In thc case of multiple doses, the percentage refers to the total dose. Each point is the average of 3 rats.
respect quite individually. The relatively easy mobilization of l"Ce from the liver is in sharp contrast to other tissues as \\-ell as to the response of 'IT.
Pertinent to the follov-ing considerations is the relath-el! small slope of the dose-effect curves. This is in keeping with analogous findings of Seidel (1963), Norwood (1962) , Rosoff, Ritter, Sullivan, Hart and SpencerLaszlo (1961) , Schubert, Fried, Rosenthal and Linderibaum (1961), Taylor and Sowby (1962) . The greater therapeutic index of Co(I1)-and, in particular, of Zn(I1)-DTPA makes a higher dosage than with Ca-DTPA feasible. However, if the small slope of the dose-effect curves is taken into account, the actual gain in therapeutic effectiveness will remain insignificant. Therefore, the sole, though essential, advantage offered by the less toxic chelates is the gain of an increased safety. Taking into account that the toxicity of Zn(I1)-DTPA, for instance, is at least ten times, but the effectiveness merely two times lower than that of Ca-DTPA, the therapeutic index is increased by a factor of > 1012 = > 5.
For the related ethylenediaminetetraacetic acid a dosage of 0.12 mM per kilogram and per day is generally recommended for humans (e.g. Foreman, Finnegan and Lushbaugh 1956, Seven 1960) . Because of the two times higher toxicity of DTPA (Catsch 1964b) , the dosage should be reduced to O.06mM Ca-DTPA per kilogram and per day. With Co(I1)-and Zn(I1)-DTPA (allowing for their possibly slightly reduced efficacy) a dosage of 0.15 mM per kilogram and per day may tentatively be considered as appropriate.
Before an unrestricted usage of both chelates in humans can be recommended, however, a crucial point remains to be settled. Although the repeated administration of relatively large doses of Zn(I1)-and Co(I1)-DTPA was not followed by lethality and nephrotic damage, there still remains the possibility that other and possibly relevant side-effects escaped observation. Referring to the results presented in figures 6 and 7, approximately 4 per cent of Zn and 0.7 per cent of CO (both administered as chelates) are retained by the body. If the assumption is made that these percentages do not depend on the size of the dose, each single dose would give rise t-o the splitting-off of approximately 0.3 mg Zn per kilogram and 0.05 mg CO per kilogramt. We are not aware of any pertinent investigations which prove unequivocally that the repeated (though restricted to a relatively short time-period) administration of doses of this order of magnitude leads to any harmful side effects. Kevertheless, experiments aiming at the elucidation of this question and giving direct evidence are urgently needed.
Der Einflul3 von Co(I1)-DTPA und Zn(I1)-DTPA auf die Verteilung von Radiocer und Radioyttrium irn Organismus der Ratte wird untersucht. Die Retentionsverhind e m g beider Chelate ist nur unwesentlich kleiner als die von Ca-DTPA. Dagegen ist der therapeutische Index beider Chelate weger ihrer geringen Toxicitat xvesentlich hoher als bei Ca-DTPA. Die aus den Resultaten sich ergebenden theoretischen und praktischen Fragen werden diskutiert.
